Cargando…
Distribution of Clostridium Difficile Ribotypes in Macedonian Patients and their Antimicrobial Susceptibility
BACKGROUND: Clostridium difficile is a major nosocomial pathogen. In Europe, this bacterium is mostly characterised by PCR ribotyping. Most of the Clostridium difficile infections (CDI) are treated with vancomycin or metronidazole, although prolonged antibiotic use is considered as one of the main r...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Republic of Macedonia
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6684425/ https://www.ncbi.nlm.nih.gov/pubmed/31406525 http://dx.doi.org/10.3889/oamjms.2019.482 |
_version_ | 1783442245092900864 |
---|---|
author | Mihajlov, Kiril Andreska, Aneta Ristovska, Nadica Grdanoska, Tatjana Trajkovska-Dokic, Elena |
author_facet | Mihajlov, Kiril Andreska, Aneta Ristovska, Nadica Grdanoska, Tatjana Trajkovska-Dokic, Elena |
author_sort | Mihajlov, Kiril |
collection | PubMed |
description | BACKGROUND: Clostridium difficile is a major nosocomial pathogen. In Europe, this bacterium is mostly characterised by PCR ribotyping. Most of the Clostridium difficile infections (CDI) are treated with vancomycin or metronidazole, although prolonged antibiotic use is considered as one of the main risk factors for CDI. AIM: This study aimed to detect the presence of various C. difficile ribotypes in hospitalised patients and to investigate their toxigenicity and antibiotic susceptibility. MATERIAL AND METHODS: All stool samples obtained from each patient were inoculated on Columbia blood agar and cycloserine cefoxitine fructose agar (CCFA) for isolation of C. difficile. Glutamate dehydrogenase and toxins A and B were investigated by immunochromatographic tests. Final confirmation of the isolates was performed by Vitek 2 and MALDI-TOF. A total of 21 isolates were collected for further investigation. PCR ribotyping was performed as described by Janezic and Rupnik. PCR ribotype profiles were analysed using software (Bionumerics, Applied Maths). Antibiotic susceptibility was determined by E-tests for metronidazole, vancomycin, tetracycline, clindamycin, erythromycin, imipenem, ciprofloxacin and moxifloxacin. RESULTS: About 48% of C. difficile isolates belonged to ribotype 001/072. So, this ribotype was the most common ribotype in this study. The remaining 52% of C. difficile isolates consisted of 10 different ribotypes: 017, SLO 160, SLO 187, SLO 120, 255/258, 014/020, 046, 002, 070 and 027. Furthermore, 20 (95.2 %) out of 21 isolates of C. difficile were toxigenic. Toxins A and B were detected simultaneously in 90.5 % of C. difficile isolates. Two isolates from the ribotype 017 were toxin B positive only. Treatments with any of the following antimicrobials: clindamycin, erythromycin, ciprofloxacin and moxifloxacin (as well as many other antibiotics), could be a risk factor for CDI due to the high resistance of the strains in this study. About 90% of the strains from the most common ribotype 001/072 have MICs for clindamycin and erythromycin > 256 µg/ml. CONCLUSION: All strains isolated are highly resistant to ciprofloxacin. All strains were susceptible to vancomycin (median MIC was 0.63 µg/ml) and metronidazole (median MIC was 0.084 µg/ml), so these two antimicrobials remain optimal treatment option for CDI. |
format | Online Article Text |
id | pubmed-6684425 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Republic of Macedonia |
record_format | MEDLINE/PubMed |
spelling | pubmed-66844252019-08-12 Distribution of Clostridium Difficile Ribotypes in Macedonian Patients and their Antimicrobial Susceptibility Mihajlov, Kiril Andreska, Aneta Ristovska, Nadica Grdanoska, Tatjana Trajkovska-Dokic, Elena Open Access Maced J Med Sci Basic Science BACKGROUND: Clostridium difficile is a major nosocomial pathogen. In Europe, this bacterium is mostly characterised by PCR ribotyping. Most of the Clostridium difficile infections (CDI) are treated with vancomycin or metronidazole, although prolonged antibiotic use is considered as one of the main risk factors for CDI. AIM: This study aimed to detect the presence of various C. difficile ribotypes in hospitalised patients and to investigate their toxigenicity and antibiotic susceptibility. MATERIAL AND METHODS: All stool samples obtained from each patient were inoculated on Columbia blood agar and cycloserine cefoxitine fructose agar (CCFA) for isolation of C. difficile. Glutamate dehydrogenase and toxins A and B were investigated by immunochromatographic tests. Final confirmation of the isolates was performed by Vitek 2 and MALDI-TOF. A total of 21 isolates were collected for further investigation. PCR ribotyping was performed as described by Janezic and Rupnik. PCR ribotype profiles were analysed using software (Bionumerics, Applied Maths). Antibiotic susceptibility was determined by E-tests for metronidazole, vancomycin, tetracycline, clindamycin, erythromycin, imipenem, ciprofloxacin and moxifloxacin. RESULTS: About 48% of C. difficile isolates belonged to ribotype 001/072. So, this ribotype was the most common ribotype in this study. The remaining 52% of C. difficile isolates consisted of 10 different ribotypes: 017, SLO 160, SLO 187, SLO 120, 255/258, 014/020, 046, 002, 070 and 027. Furthermore, 20 (95.2 %) out of 21 isolates of C. difficile were toxigenic. Toxins A and B were detected simultaneously in 90.5 % of C. difficile isolates. Two isolates from the ribotype 017 were toxin B positive only. Treatments with any of the following antimicrobials: clindamycin, erythromycin, ciprofloxacin and moxifloxacin (as well as many other antibiotics), could be a risk factor for CDI due to the high resistance of the strains in this study. About 90% of the strains from the most common ribotype 001/072 have MICs for clindamycin and erythromycin > 256 µg/ml. CONCLUSION: All strains isolated are highly resistant to ciprofloxacin. All strains were susceptible to vancomycin (median MIC was 0.63 µg/ml) and metronidazole (median MIC was 0.084 µg/ml), so these two antimicrobials remain optimal treatment option for CDI. Republic of Macedonia 2019-06-30 /pmc/articles/PMC6684425/ /pubmed/31406525 http://dx.doi.org/10.3889/oamjms.2019.482 Text en Copyright: © 2019 Kiril Mihajlov, Aneta Andreska, Nadica Ristovska, Tatjana Grdanoska, Elena Trajkovska-Dokic. http://creativecommons.org/licenses/CC BY-NC/4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0). |
spellingShingle | Basic Science Mihajlov, Kiril Andreska, Aneta Ristovska, Nadica Grdanoska, Tatjana Trajkovska-Dokic, Elena Distribution of Clostridium Difficile Ribotypes in Macedonian Patients and their Antimicrobial Susceptibility |
title | Distribution of Clostridium Difficile Ribotypes in Macedonian Patients and their Antimicrobial Susceptibility |
title_full | Distribution of Clostridium Difficile Ribotypes in Macedonian Patients and their Antimicrobial Susceptibility |
title_fullStr | Distribution of Clostridium Difficile Ribotypes in Macedonian Patients and their Antimicrobial Susceptibility |
title_full_unstemmed | Distribution of Clostridium Difficile Ribotypes in Macedonian Patients and their Antimicrobial Susceptibility |
title_short | Distribution of Clostridium Difficile Ribotypes in Macedonian Patients and their Antimicrobial Susceptibility |
title_sort | distribution of clostridium difficile ribotypes in macedonian patients and their antimicrobial susceptibility |
topic | Basic Science |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6684425/ https://www.ncbi.nlm.nih.gov/pubmed/31406525 http://dx.doi.org/10.3889/oamjms.2019.482 |
work_keys_str_mv | AT mihajlovkiril distributionofclostridiumdifficileribotypesinmacedonianpatientsandtheirantimicrobialsusceptibility AT andreskaaneta distributionofclostridiumdifficileribotypesinmacedonianpatientsandtheirantimicrobialsusceptibility AT ristovskanadica distributionofclostridiumdifficileribotypesinmacedonianpatientsandtheirantimicrobialsusceptibility AT grdanoskatatjana distributionofclostridiumdifficileribotypesinmacedonianpatientsandtheirantimicrobialsusceptibility AT trajkovskadokicelena distributionofclostridiumdifficileribotypesinmacedonianpatientsandtheirantimicrobialsusceptibility |